Navigation Links
Sanofi Announces Positive Results from the "All to Target" Study Evaluating Two Lantus® and Apidra® Regimens Versus Premixed Regimen
Date:6/24/2011

PARIS, June 24, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data from a 60-week, open-label study that compared three intensified insulin regimens added to oral therapy for uncontrolled type 2 diabetes and found that using two regimens including Lantus® (insulin glargine [rDNA origin] injection) and Apidra® (insulin glulisine [rDNA origin] injection) lowered blood glucose levels compared to premixed insulin with less hypoglycemia and improvement in diabetes-specific quality of life.

(Logo: http://photos.prnewswire.com/prnh/20110624/NY25833LOGO)

"Optimization of insulin dosage with glargine plus a single mealtime injection of glulisine allowed more patients to reach target A1C levels than with twice-daily premixed insulin, and with less hypoglycemia," said Matthew Riddle, MD, head of the Oregon Health and Science University Section of Diabetes and lead investigator of one of the data analyses presented at the meeting. "These findings support a stepwise approach to addition of mealtime insulin when basal insulin with oral agents is not sufficient to maintain control."

Three analyses of this data are being either presented or published at the American Diabetes Association's 71st Scientific Sessions in San Diego, California.

About the "All to Target" StudyThe study was designed to evaluate glycemic control achieved by three intensified insulin regimens with two co-primary objectives: 1) to demonstrate superiority of Lantus® plus up to 3 injections of mealtime Apidra® versus premixed insulin, as measured by A1c<7% at week 60; and 2) to demonstrate non-inferiority of Lantus® plus up to 1 injection of mealtime Apidra® versus premixed insulin, based on the reduction from baseline to week 60.

Investigators compared the addition of twice-daily Novolog® (insulin aspart) Mix 70
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medco, United BioSource and Sanofi Signed Global Agreement to Improve Quality of Patient Care Through Real-World Evidence
2. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
3. Sanofi Pasteur Donates Tdap Vaccine to Aid Storm Victims
4. sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
5. Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants
6. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
7. Sanofi-Aventis Completes Acquisition of Genzyme Corporation
8. Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation
9. Navinta LLC is Pleased to Announce US FDA Approval of Sodium Ferric Gluconate Injection in Sucrose [a generic equivalent of Ferrlecit® Injection by Sanofi Aventis] Based on Its Proprietary Technology
10. Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective
11. Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
(Date:7/10/2014)...  Decision Resources Group finds that while more ... are willing to prescribe Durata,s Dalvance (dalbavancin) and ... OPAT, approximately two-thirds of the respondents reported a ... inpatients. However, our findings indicate that nearly two-thirds ... OPAT following hospital discharge, and most are discharged ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Resveratrol, Sirtuin1 gene Target Discredited; Lower Dose, Array ... Small Molecules (Longevinex(R)) Exert Greater Effect, SAN ... wine molecule,resveratrol (rez-vair-ah-trawl) has recently attracted scientific and,public ... the effects,of a calorie-restricted diet, the science surrounding ...
... Alpharma Inc.,(NYSE: ALO ), a global ... Phase III pivotal efficacy trial that showed ... capsules provided significant pain relief in patients ... of the hip or knee compared,to placebo. ...
Cached Medicine Technology:Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged 2Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged 3Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged 4Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 2Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 3Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 4Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 5
(Date:7/12/2014)... July 12, 2014 With prom shopping ... manufacturer and retailer, is ready to showcase its new ... new collection of evening dresses in its online shop. ... 67% off) for these elegant gowns. According to the ... end on July 26, 2014. , He says, ...
(Date:7/12/2014)... Wright & Schulte LLC has filed a DePuy Pinnacle ... Johnson & Johnson, on behalf of an Ohio man who ... DePuy Pinnacle hip replacement and had to undergo revision surgery ... DePuy hip lawsuit was filed July 7, 2014, in the ... where DePuy Pinnacle Hip lawsuit litigation is underway . ...
(Date:7/12/2014)... July 12, 2014 Doylestown Hospital recently ... variety of men’s health questions. Paddock tackles topics ... men, why women live longer than men, and testosterone ... Health Made Simple featured on Doylestown Hospital’s website, ... hernia at any age. If you notice pain, bulging, ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Utah Valley ... of startups, with awards being bestowed to companies in ... Utah’s outstanding entrepreneur community with recognition for new ideas ... model with incoming revenue. , 25 Under 5 highlights ... state that are under 5 years old. Award recipients ...
(Date:7/12/2014)... article released by Seattle's well known plastic surgeon, Dr. Bryan ... cosmetic surgical procedures in summer months . , As ... enliven the rainy Pacific Northwest, many people are turning their ... out as much during the winter as they had planned. ... eager to look their best for their summer vacations, and ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
... and regulatory actions make great strides toward establishing ... to develop and test more medications for pediatric ... by experts from Children,s National Medical Center ... issue of Science Translational Medicine. ...
... to research conducted at the Oregon National Primate Research Center ... that oral contraceptives cause weight gain appears to be false. ... appear in next month,s edition of the journal Human ... reveal that contraceptives and the possibility that they may cause ...
... 20, 2011) Cancer scientists led by Dr. John ... at St Jude Children,s Research Hospital (Memphis) have found ... carry them are organized in a more complex way ... in Nature (DOI:10.1038/nature09733), challenge the conventional scientific ...
... N.Y. (January 19, 2011) Autism Speaks, North America,s ... announce the expansion of its Autism Treatment Network to ... in the U.S. and Canada. The Autism Speaks Autism ... and healthcare for children and adolescents with autism spectrum ...
... -- Parents may have good reason to be concerned ... playing their new video games since the holidays. A ... an Iowa State University psychologist -- found further evidence ... amounts of gaming, lower social competence and greater impulsivity ...
... is available in German . Malignant ... depending on disease stage. Experts hope that the examination of ... helpful in the choice of the right treatment than other ... and Efficiency in Health Care (IQWiG) has now investigated the ...
Cached Medicine News:Health News:Science Translational Medicine: 'Creating Hope Act' incentivizes pediatric drug R&D 2Health News:Do birth control pills cause weight gain? New research says no 2Health News:Cancer scientists discover genetic diversity in leukemic propagating cells 2Health News:Cancer scientists discover genetic diversity in leukemic propagating cells 3Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 2Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 3Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 4Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 5Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 6Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 7Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 8Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 9Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 10Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 11Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 12Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 13Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 14Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 15Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 16Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 17Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 18Health News:New Pediatrics study identifies the risks, consequences of video game addiction 2Health News:New Pediatrics study identifies the risks, consequences of video game addiction 3Health News:Malignant brain tumors: Benefit of PET and PET/CT in the detection of recurrences is not assessable 2
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists....
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
Electric high speed system....
The Durafuge 100 spins swing-out rotors at 4000 rpm and fixed-angle rotors at up to 6300 rpm....
Medicine Products: